{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Hepatocellular+Carcinoma+AJCC+v7&page=2", "query": { "condition": "Stage IV Hepatocellular Carcinoma AJCC v7", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+IV+Hepatocellular+Carcinoma+AJCC+v7&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:35:16.627Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05038254", "title": "Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Clinical Stage IV Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IV Gastric Cancer AJCC v8", "Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVA Gastric Cancer AJCC v8", "Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8", "Clinical Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Clinical Stage IVB Gastric Cancer AJCC v8", "Metastatic Colon Carcinoma", "Metastatic Esophageal Carcinoma", "Metastatic Gastric Carcinoma", "Metastatic Liver Carcinoma", "Metastatic Malignant Digestive System Neoplasm", "Metastatic Malignant Small Intestinal Neoplasm", "Metastatic Malignant Thoracic Neoplasm", "Metastatic Pancreatic Carcinoma", "Metastatic Rectal Carcinoma", "Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IV Gastric Cancer AJCC v8", "Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8", "Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8", "Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8", "Stage IV Colon Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Stage IV Rectal Cancer AJCC v8", "Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor AJCC v8", "Stage IVA Colon Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Rectal Cancer AJCC v8", "Stage IVB Colon Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Rectal Cancer AJCC v8", "Stage IVC Colon Cancer AJCC v8", "Stage IVC Rectal Cancer AJCC v8" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Patient Monitoring", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 750, "start_date": "2021-05-12", "completion_date": "2026-01-31", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-05-21T23:35:16.627Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05038254" }, { "nct_id": "NCT06968195", "title": "Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Hepatocellular Carcinoma", "Metastatic Hepatocellular Carcinoma", "Recurrent Hepatocellular Carcinoma", "Refractory Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Anti-GPC3-CAR Autologous T Lymphocytes", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2026-05-01", "completion_date": "2029-05-30", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-05-21T23:35:16.627Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06968195" }, { "nct_id": "NCT05168163", "title": "Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Hepatocellular Carcinoma", "Metastatic Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Lenvatinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2022-05-27", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-09-16", "last_synced_at": "2026-05-21T23:35:16.627Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Weston, Florida + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Weston", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Urbana", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05168163" }, { "nct_id": "NCT04175912", "title": "Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Cholangiocarcinoma", "Metastatic Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Intrahepatic Cholangiocarcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Cholangiocarcinoma", "Unresectable Hepatocellular Carcinoma", "Unresectable Intrahepatic Cholangiocarcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pevonedistat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2020-03-16", "completion_date": "2026-10-31", "has_results": true, "last_update_posted_date": "2026-05-20", "last_synced_at": "2026-05-21T23:35:16.627Z", "location_count": 420, "location_summary": "Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 254 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04175912" }, { "nct_id": "NCT03695250", "title": "BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Unresectable Hepatocellular Carcinoma" ], "interventions": [ { "name": "IDO1 Inhibitor BMS-986205", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Edward Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-10-16", "completion_date": "2021-03-12", "has_results": true, "last_update_posted_date": "2023-08-22", "last_synced_at": "2026-05-21T23:35:16.627Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03695250" }, { "nct_id": "NCT05092373", "title": "Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Carcinoma", "Advanced Endometrial Carcinoma", "Advanced Fallopian Tube Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Malignant Abdominal Neoplasm", "Advanced Malignant Female Reproductive System Neoplasm", "Advanced Malignant Thoracic Neoplasm", "Advanced Ovarian Carcinoma", "Advanced Primary Peritoneal Carcinoma", "Advanced Renal Cell Carcinoma", "Anatomic Stage III Breast Cancer AJCC v8", "Anatomic Stage IIIA Breast Cancer AJCC v8", "Anatomic Stage IIIB Breast Cancer AJCC v8", "Anatomic Stage IIIC Breast Cancer AJCC v8", "Anatomic Stage IV Breast Cancer AJCC v8", "Malignant Abdominal Neoplasm", "Malignant Solid Neoplasm", "Metastatic Breast Carcinoma", "Metastatic Endometrial Carcinoma", "Metastatic Fallopian Tube Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Malignant Abdominal Neoplasm", "Metastatic Malignant Female Reproductive System Neoplasm", "Metastatic Malignant Thoracic Neoplasm", "Metastatic Ovarian Carcinoma", "Metastatic Primary Peritoneal Carcinoma", "Metastatic Renal Cell Carcinoma", "Prognostic Stage III Breast Cancer AJCC v8", "Prognostic Stage IIIA Breast Cancer AJCC v8", "Prognostic Stage IIIB Breast Cancer AJCC v8", "Prognostic Stage IIIC Breast Cancer AJCC v8", "Prognostic Stage IV Breast Cancer AJCC v8", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage III Uterine Corpus Cancer AJCC v8", "Stage IIIA Fallopian Tube Cancer AJCC v8", "Stage IIIA Hepatocellular Carcinoma AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Primary Peritoneal Cancer AJCC v8", "Stage IIIA Uterine Corpus Cancer AJCC v8", "Stage IIIA1 Fallopian Tube Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Fallopian Tube Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Fallopian Tube Cancer AJCC v8", "Stage IIIB Hepatocellular Carcinoma AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Primary Peritoneal Cancer AJCC v8", "Stage IIIB Uterine Corpus Cancer AJCC v8", "Stage IIIC Fallopian Tube Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Primary Peritoneal Cancer AJCC v8", "Stage IIIC Uterine Corpus Cancer AJCC v8", "Stage IIIC1 Uterine Corpus Cancer AJCC v8", "Stage IIIC2 Uterine Corpus Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8", "Stage IV Uterine Corpus Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Hepatocellular Carcinoma AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVA Uterine Corpus Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Hepatocellular Carcinoma AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8", "Stage IVB Uterine Corpus Cancer AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Tumor Treating Fields Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2022-04-29", "completion_date": "2026-09-01", "has_results": false, "last_update_posted_date": "2026-01-14", "last_synced_at": "2026-05-21T23:35:16.627Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05092373" }, { "nct_id": "NCT02940496", "title": "Pembrolizumab (MK-3475) in Hepatocellular Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "BCLC Stage B Hepatocellular Carcinoma", "BCLC Stage C Hepatocellular Carcinoma", "Hepatitis C Infection", "Refractory Liver Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v7", "Stage IIIA Hepatocellular Carcinoma AJCC v7", "Stage IIIB Hepatocellular Carcinoma AJCC v7", "Stage IIIC Hepatocellular Carcinoma AJCC v7", "Stage IV Hepatocellular Carcinoma AJCC v7", "Stage IVA Hepatocellular Carcinoma AJCC v7", "Stage IVB Hepatocellular Carcinoma AJCC v7" ], "interventions": [ { "name": "Elbasvir/Grazoprevir", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2016-12-09", "completion_date": "2023-08-09", "has_results": true, "last_update_posted_date": "2025-07-15", "last_synced_at": "2026-05-21T23:35:16.627Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02940496" }, { "nct_id": "NCT07166406", "title": "Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Hepatocellular Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "RADIATION" }, { "name": "Tremelimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2026-02-26", "completion_date": "2029-03-10", "has_results": false, "last_update_posted_date": "2026-05-04", "last_synced_at": "2026-05-21T23:35:16.627Z", "location_count": 107, "location_summary": "Berkeley, California • Cameron Park, California • Fremont, California + 83 more", "locations": [ { "city": "Berkeley", "state": "California" }, { "city": "Cameron Park", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Mountain View", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07166406" }, { "nct_id": "NCT07405086", "title": "Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Advanced Biliary Tract Carcinoma", "Advanced Head and Neck Squamous Cell Carcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Lung Non-Small Cell Carcinoma", "Advanced Malignant Solid Neoplasm", "Advanced Melanoma", "Advanced Renal Cell Carcinoma", "Metastatic Biliary Tract Carcinoma", "Metastatic Head and Neck Squamous Cell Carcinoma", "Metastatic Hepatocellular Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Recurrent Head and Neck Squamous Cell Carcinoma", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage III Renal Cell Cancer AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Immune Checkpoint Inhibitor", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2026-05-05", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-21T23:35:16.627Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT07405086" }, { "nct_id": "NCT05791448", "title": "AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cholangiocarcinoma", "Advanced Hepatocellular Carcinoma", "Advanced Malignant Solid Neoplasm", "Metastatic Malignant Neoplasm in the Liver", "Refractory Malignant Solid Neoplasm", "Stage III Hepatocellular Carcinoma AJCC v8", "Stage IV Hepatocellular Carcinoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "RNA Transcription Modulator AU-409", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Southern California", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 36, "start_date": "2023-03-29", "completion_date": "2027-03-29", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-05-21T23:35:16.627Z", "location_count": 2, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05791448" } ] }